stimulants and since when each combinations is being marketed;

(c) what is the composition of each;

(d) what are the names of five brands of each combination, name of the producer and the price of each;

(e) whether it is a fact that all these combinations are irrational, useless and dangerous;

(f) whether the expert committee set up by his Ministry for withdrawal of irrational combinations have considered these combinaions; and

(g) if so, what is their reaction on each combination and if not, the reasons therefor?

THE MINISTER OF STATE OF THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI RAFIQUE ALAM): (a) and (b) The Expert Sub-Committee of the Drugs Consultative Committee is engaged in examination of formulations moving in the market, licensd by State Drug Controllers, from the angle of therapeutic efficacy, safety and rationality in the context of the knowledge presently available. Such examination would also include rationality of combinations of enzyme with anti-inflamatory agents, psychotherapeutic combinations, anti-diarrhoeal combinations tonics, etc. which are in the market for many years.

(c) and (d) The detailed composition of combinations named above including their brand names, name of the manufacturer as well as the retail price of each brand is accessible in the Monthly Index of Medical Specialities (MIMS INDIA), Volume 9, No. 7, July, 1989 published by MIMS India, 90 Nehru Place, New Delhi-110019.

(e), (f) and (g) The Experts Committee have not yet examined the above combinations except that it has done an exercise in streamlining the tonics. However, the report of the experts committee has to be examined by the Drugs Consultative Committee (DCC) and the Drugs Technical Advisory Board (DTAB), statutory bodies under the Drugs and Cosmetics Act.

Marketing of Combinations of Drugs

2632. SHRI P. N. SUKUL:

DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that combination of Diazapam with Vitamin B 6, Chlordiazepoxide with Amitrytaline, Haloperidal wih Trithexpemidyl and Chlordizepoxide with Cledinth are being marketed in the country;

(b) if so, the names of five brands of each being marketed, alongwith the composition of each and the name of manufacturer of each;

(c) whether it is a fact that all these combinations are irrational and injurious for human consumption;

(d) what are the advantage, the side-effect, contraindiction and dangerous effects of each combination; and

(e) what steps are being taken by the Ministry of Health and Family Welfare to stop marketing of these combinations?

THE MINISTER OF STATE OF THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI RAFIQUE ALAM): (a) The combination mentioned under part (a) of the question have been licensed by the State Drug Control Authorities for marketing in the country.

(b) The different grands of the various commbinations mentioned in part (a) of the question alongwith the composition as well as the name of the manufacturer are accessible in the Monthly Index of Medical Specialities, Volume 9, No. 7, July, 1989 published by MIMS India, No. 98 Nehru Place, New Delhi-110019.

(c) and (d) The above combinations have not been reviewed by the experts

sub-committee of the Drugs Consultative Committee (DCC) and as such has not commented on these combinations.

(e) Does not arise.

Marketing of Digestive Enzymes

2633. SHRI ASHOK NATH VERMA:
DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that digestive enzymes are being marketed in the country;

(b) what are the details of composition allowed for marketing;

(c) whether his Ministry considered the rationale for quantity, dosage form and combinations of each;

(d) if so, the details thereof;

(e) whether it is a fact that his Ministry have found a number of these products irrational, as far as the quantity, dosage form and combinations of other drugs are concerned;

(f) if so, the names of such compositions;

(g) what steps have been taken to ban these compositions; and

(h) by when the action would be taken and irrational compositions banned?

THE MINISTER OF STATE OF THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI RAFIQUE ALAM): (a) Yes, Sir.

(b) Details of enzyme preparations, licensed by the State Drug Controller, marketed in India, are given in the Statement-I. (*See* below).

(c) The sub-committee of experts of the Drugs Consultative Committee has reviewed and examined the enzyme preparations moving in the market.

(d) to (h) A statement-II is enclosed. (*See* below).

Statement I

Popular Enzyme Preparations

ALVIZYME ALEMBIC
Pancr atin 125mg, (having amylase activity not less than 750u. protease activity not less than 3000u. & lipase activity not less than 640 u.) simethicone 25 mg. tabs.

PARIZYM FORTE Infar
Lipase not less than 6000 fip u. protease not less than 350 fip u. amylase not less than 4000 fip u. cellulase to an activity of 2.5 w.u. cholic acid (as bile ext.) 30 mg; tabs.

BESTOZYME BIOLOGICAL-E
Alpha amylase (1:250) 320 mg, papain 60 mg, activated dimethicone 40mg; cap.

DIGEPLEX Rallis
Diastase (1:250) 20mg, pepsin 20 mg. vit. B-1 1mg, B-2 1mg, B-6 0.5 mg, dipantothenyalcohol 25mg, nicotinamide 10 mg, B-12 0.5 mg, per 10ml; liq. (Tabs. cont. diastase, vit. B-12 supplied. separate to be crushed and mised before intake)

DISPEPTAL Boehnnger-K
Pancreatin 150mg, veg. enzymes 33mg (equiv. to cellulases & hemicellulases activity of 6 Grassmann units), bile salts 25 mg, dragees.

DIZYTONE Unichem
Fungal diattase (1:75) 900 mg, vit. B-1 6 mg, B-2 5 mg, B-6 1.5 mg, B-12 5 mg niacinamide 48 mg, d-panthenol 5 mg. per 15 ml, syrup.

ENZYMES SYRUP IPCA
Fungal diastase (1.50) 500 mg, pepsin 15 mg, vit. B-1 2.5 mg, B-2 2.5 mg, nicotinamide 22.5 mg, d-panthenol 2.5 mg, B-6 1mg, methylpotysiox. 20 mg, per 5 ml.

VITAZYME East India
Fungal diastase (1:2000) 20 mg. vit. B-1 0 3 mg, B-2 0.5 mg, B-6 0.25 mg, nicotinamide 4 mg. per 5 ml. liq.

FESTAL HOECHST
Pancreatin 192 mg, bile constituents 25 mg, hemicellulase 50 mg, dragees.